Journal
FEBS LETTERS
Volume 588, Issue 2, Pages 269-277Publisher
WILEY
DOI: 10.1016/j.febslet.2013.11.029
Keywords
Protein engineering; Antibody therapeutics; Protein aggregation; Stability
Ask authors/readers for more resources
Human monoclonal antibodies often display limited thermodynamic and colloidal stabilities. This behavior hinders their production, and places limitations on the development of novel formulation conditions and therapeutic applications. Antibodies are highly diverse molecules, with much of the sequence variation observed within variable domain families and, in particular, their complementarity determining regions. This has complicated the development of comprehensive strategies for the stability engineering of the human antibody repertoire. Here we provide an overview of the field, and discuss recent advances in the development of robust and aggregation resistant antibody therapeutics. Crown Copyright (C) 2013 Published by Elsevier B. V. on behalf of Federation of European Biochemical Society. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available